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Mycobacterium tuberculosis is still one of the most significant 
human pathogens since it was discovered[1]. It is an intracellular 
pathogen surviving and replicating within macrophages[2]. Knowledge of 
the bacteria-macrophage interaction can help develop novel measures to 
combat tuberculosis. Macrophage models are of great importance for 
studies on tuberculosis because the environment can be simulated for the 
growth of mycobacterium tuberculosis with macrophage models. In this 
article we review cell sources and applications of macrophage models for 
tuberculosis studies.  
 
2. Methods 
The online English database PubMed, Chinese databases CNKI, 
SinoMed, and Wanfang were searched up to December 2010 for 
published articles. Two groups of terms were used for the information 
retrieval, one of which includes macrophage model and macrophage; the 
other group of terms are composed of comprises mycobacterium 
tuberculosis. For PubMed, the two groups of English terms were applied, 
while Chinese terms were used.  
Inclusion criteria were set up for this review, by which articles 
on cell sources, screening of anti-tuberculosis drugs, pathogenic 
mechanisms of tuberculosis or immunomechanism of tuberculosis of 
macrophage models are collected. Exclusion criteria were also developed, 
by which articles about other aspects of macrophage models, such as 




Thirty-seven articles met the inclusion criteria, most of which 
are from PubMed. The topics in these articles are cell sources, screening 
of anti-tuberculosis drugs, pathogenesis and immunomechanism of 
tuberculosis with the application of macrophage models.  
2.1. Development of Macrophage Models 
Slayden et al established a macrophage model in the way 
described below: the marrow of six- to eight-week-old female specific-
pathogen-free C57BL/6 mice was flushed from their femurs. The marrow 
plugs were disrupted by gentle pipetting, washed twice, and plated at 
tissue culture treated plates. After 48 hours of incubation, the 
nonadherent cells were removed and new sDMEM was added. The cells 
were washed after a further 4 days, and antibiotic-free medium was 
added and incubated for 2 more days. Eight days after plating, 
macrophages were infected with M. tuberculosis Erdman in 200 µl of 
medium for 2 hours, and then extensively washed to remove 
extracellular bacteria[3].  
Zhao et al developed a macrophage model in the following 
steps: cells of human monocytic cell line THP1 were cultured without 
antibiotics. THP1 cells were seeded into the wells of tissue culture plates. 
Phorbol 12-myristate 13-acetate was added to each well at a final 
concentration of 100 nM after incubation. Finally, mycobacteria were 
added after one additional hour of incubation[4].  
According to Eddine et al, a macrophage model was made as 
follows: bone marrow-derived macrophages were extracted from 
C57/BL6 mice and seeded in culture dishes. They were allowed to 
differentiate for 5 to 6 days in Dulbecco's modified essential medium. 
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These cells were then seeded in 96-well plates and incubated overnight 
for adhesion[5].  
2.2. Cell Sources of Macrophage Models 
2.2.1 Murine Bone Marrows 
Murine bone marrows are one of the cell sources for 
macrophage models. Bone marrow-derived macrophages can be 
obtained from C57BL/6 female mice[6]. Mice can be killed by exposure to 
CO2 with the femur bones dissected out. Their bones are trimmed at each 
end, and the marrow is washed out using Dulbecco’s minimal essential 
medium (DMEM) supplemented with fetal calf serum, L-929 fibroblast 
conditioned supernatant, HEPES buffer, nonessential amino acids, L-
glutamine, and antibiotics. Cell suspensions is then washed twice and 
plated in supplemented DMEM.  
According to Pichugin et al, macrophages were isolated from 
femurs and tibias of male mice for macrophage models by centrifugation 
at room temperature on a NycoPrep gradient, washed, and cultured in 
tissue culture flasks in supplemented DMEM. The nonadherent cells were 
harvested and transferred into tissue culture flacks. Nonadherent cells 
were harvested, washed, and plated to tissue culture plates in the same 
medium without IL-3. Finally the cells were maintained by feeding with 
fresh medium to form monolayer[7]. 
BALB/c mice can also be the source for building macrophage 
models. Bashir N et al reported that RAW 264.7 macrophages were 
washed with wash buffer twice and then incubated with rRv2626c for 
various times on ice. These macrophages were incubated with the anti-
Rv2626c antibody followed by incubation with anti-mouse fluorescein 
isothiocyanate conjugate after washing, suspended in sheath fluid, and 
analysed on a fluorescence-activated cell sorter machine after a final 
washing[8]. 
2.2.2 Human Peripheral Blood 
Another cell source of macrophage models is human 
peripheral blood. Nair et al[9] reported that, in order to obtain a 
macrophage model, monocyte-derived macrophages were isolated from 
heparinized blood from the vein of the healthy participants. Cells were 
collected from the interface. Adherent monolayers were harvested by 
incubating the peripheral blood monocytes in tissue culture plates. 
Nonadherent cells were removed with a transfer pipette and used for 
purifying T cells[9].  There are some other scholars who also used human 
peripheral blood for setting up macrophage models[10][11].  
2.2.3 Human Lungs 
Bronchoalveolar cells are also a source of macrophage models. 
According to Juarez et al the bronchoscope was used, and 0.9% sterile 
saline fluid was instilled into each of two adjacent lung subsegments. 
Bronchoalveolar lavage fluid was centrifuged. The bronchoalveolar cells 
were resuspended in culture medium and their viability was assessed 
using Trypan blue exclusion[12].  
2.2.4 Cell Lines 
In addition, cell lines are one of the cell sources for 
macrophage models. According to Tominaga et al a macrophage cell line 
with activated characters and unique morphology is isolated from the 
human monocytic cell line THP-1. The original THP-1 cells have been 
cultured for years. When they appear to be cells with a different 
morphology, the cells adhere to the bottoms of the culture flasks. The 
adherent cells are selected by discarding floating nonadherent cells at 
every subculture. Enrichment of adherent THP-1 cells with long 
processes proceeds. Adherent THP-1 cells indicate phenotypic changes, 
not only morphologically, but also functionally. The adherent cell line is 
taken as activated-THP-1 (A-THP-1), because it shows characteristics of 
activated macrophages continuously without extra stimulation, providing 
a good model for understanding of activation mechanisms of 
macrophages and multinucleation[13]. Some other researchers also 
reported that cells of human monocytic cell line THP1 were cultured and 
then seeded into tissue culture plates to set up a macrophage 
model[4][9][14]. 
2.3. Applications of Macrophage Models to Tuberculosis Studies 
2.3.1 Screening Antituberculosis Drugs 
Crowle described a technique to treat with chemotherapy 
human macrophages infected ex vivo with tubercle bacilli. The infected 
phagocytes interacted with such drugs as streptomycin, ethambutol, 
pyrazinamide, isoniazid, and ceforanide[15].  
Rastogi et al investigated the actions of ciprofloxacin and 
ofloxacin against M. tuberculosis with a TB-infected macrophage model in 
which the J-774 macrophage cell line was infected with the H37Rv type 
strain of M. tuberculosis.  The two tested drugs were added after 2 days of 
intracellular growth of the bacteria. They came to a conclusion that both 
drugs did not affect macrophage viability, and were effective against the 
virulent tubercle bacilli[16].  
A study by Sbarbaro et al finds a higher bacteriostatic effect 
when low, nonbactericidal levels of rifampin are combined with 
pyrazinamide but not with higher bactericidal levels of rifampin.  The 
way to introduce the drugs affects the result. Giving pyrazinamide after 
the introduction of rifampin increased the killing effect, while adding 
rifampin after the introduction of pyrazinamide resulted in a weaker 
activity than giving the agents simultaneously[17]. 
Rifabutin, clarithromycin, and ethambutol were tested by 
Furney et al for their capacities to inhibit the growth of two isolates of 
Mycobacterium avium in mice and in vitro in a macrophage model. In the 
latter model, rifabutin and clarithromycin showed modest level of 
activities against strain 101 and somehow better activities against strain 
2-151. When all of the three drugs were given in combination, they 
indicated the best results against strain 101, but no significant 
improvement compared with the result of clarithromycin given 
alone[18]. 
Sbarbaro et al quantified the intramacrophage 
antimycobacterial effect of pyrazinamide (PZA) with ofloxacin. As a 
result, a clinically achievable level of PZA strengthens the 
antimycobacterial effect of low, non-bactericidal levels of ofloxacin and 
does not hinder the bactericidal effect of a higher level of ofloxacin[19]. 
Kelly et al tested four rifamycins, which includes rifampin, 
rifabutin, rifapentine, and KRM-1648, in an in vitro murine macrophage 
model and then in the low-dose aerosol infection model, for their effects 
against M. tuberculosis. In both models, KRM-1648 showed the highest 
level of activity among all the tested drugs. In the infected-lung model, 
rifabutin, rifapentine, and KRM-1648 all sterilized the bacterium when 
given orally at 5 mg/kg per day. With a daily dose of 2.5 mg/kg, KRM-
1648 exerted the highest level of activity among these four rifamycins, 
reducing the bacterial load[20].  
Thiolactomycin (TLM) has in vivo antimycobacterial activity 
against the virulent strain M. tuberculosis Erdman, shwoing complete 
inhibition of growth on solid media at 25 micrograms/ml. In an in vitro 
murine macrophage model, the killing of viable intracellular M. 
tuberculosis in a dose-dependent manner was also seen[3]. 
In a human macrophage model infected by wild-type 
Mycobacterium bovis BCG, the C-8 methoxyl group decreased survival 20- 
to 100-fold compared with the same concentration of a C-8-H 
fluoroquinolone, improving fluoroquinolone action against both 
quinolone-susceptible and -resistant clinical isolates. Therefore, a C-8 
methoxyl group strengthens the bactericidal activity of quinolones with 
N1-cyclopropyl substitutions, implying that further refinement of 
fluoroquinolones could be done as antituberculosis agents[4]. 
Isoxyl (ISO), a thiourea (thiocarlide; 4,4′-
diisoamyloxythiocarbanilide), showed effective activity against the 
clinical isolates of M. tuberculosis from different geographical areas with 
various drug resistance patterns. In a murine macrophage model, ISO 
indicated bactericidal killing of viable intracellular M. tuberculosis in a 
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dose-dependent manner, inhibiting the synthesis of both fatty acids and 
mycolic acids at its MIC for M. tuberculosis, while both isoniazid and 
ethionamide demonstrated similarity in inhibition of the synthesis of all 
kinds of mycolic acids only. In addition, a homologous series of ISO 
derivatives were synthesized, most of which were as effective as or more 
effective than the parent compound. Therefore, these thioureas 
demonstrate promise in counteracting a big variety of strains of M. 
tuberculosis[21]. 
Two of the isoniazid derivatives with MIC < 3.13 microg/ml 
and SI > 10 were tested by Szymańska et al for efficacy in vitro in a TB-
infected macrophage model. As a result, none of them demonstrated 
satisfactory activity[22].  
Foroumadi et al evaluated a series of piperazinyl quinolones 
for their antituberculosis activity against M. tuberculosis H37Rv with the 
BACTEC 460 radiometric system and BACTEC 12B medium. It was 
indicated that compounds 1a, 1e and 1g were efficient antimycobacterial 
agents. In their study, compound 1a was also examined for efficacy in a 
macrophage model[23]. 
Qian Zhongqing established macrophage models to test the 
efficacy of Isoniazid, extract of Pittosporum Brevicalyx (Oliv.) Gagnep 
against M. tuberculosis. It is concluded that the two tested drugs are 
effective[24]. 
Maccari et al tested antimycobacterial activities of cobalt (II) 
and copper (II) complexes of fluorinated isonicotinoylhydrazones in M. 
tuberculosis-infected macrophage model. They came to a conclusion that 
all metalcomplexes indicated great activity against M. tuberculosis 
Erdman and single-drug-resistant M. tuberculosis strains[25].  
Maccari et al reported that some hydrazides and 
isonicotinoylhydrazones (ISNEs) are more effective antimycobacterial 
agents than their parental isoniazid in a TB-infected macrophage 
model[26]. 
One of the six carbazole alkaloids from the CH2Cl2 extract of 
the stem bark of Micromelum hirsutum, which is also called micromolide. 
It indicated potent in vitro anti-TB activity against H37Rv, and exhibited 
activity against the Erdman strain of M. tuberculosis in a J774 mouse 
macrophage model[27]. 
In a study by Boyne et al two high-affinity alkyl-substituted 
diphenyl ethers, 6PP and 8PP, were tested for their in vitro activity 
against clinical isolates of M. tuberculosis. The two substances showed 
enhanced activity against bacteria in a macrophage model of 
infection[28]. Eddine AN et al reported the inhibition of the growth of M. 
tuberculosis by 4,4'-dihydroxybenzophenone (DHBP) in a mouse 
macrophage model, while no cell toxicity was detected for DHBP up to 
200 μm[5]. 
In vitro, morphine did not show any direct anti-mycobacterial 
activity up to 1x10(-4) M concentration, which was assessed by 
radiometric BACTEC method. In a macrophage model of infection, 
morphine indicated maximal killing at 1x10(-7) M concentration, but was 
blocked by naloxone and aminoguanidine. These results suggest that 
morphine has a dose-dependent effect in murine tuberculosis, while its 
protective effect is naloxone-reversible and may involve macrophage-
mediated protective mechanisms[29]. 
Wu Guodong et al established peritoneal macrophage models 
for screening anti-TB drugs such as Rifampin, Ranunculus Ternatus 
Thunb, and Xinlaoning Capsule. As a result, the three drugs showed anti-
mycobacterial effects while Ranunculus Ternatus Thunb and Xinlaoning 
Capsule indicated weaker bactericidal effects than Rifampin[30].   
2.3.2 Pathogenic Mechanisms of Tuberculosis 
Horgen et al examined the postantibiotic effects (PAEs) of four 
agents against Mycobacterium avium with a macrophage model. They 
created two different experimental conditions. For postantibiotic 
leukocyte enhancement (PALE), the bacteria were exposed to antibiotics 
before phagocytosis. For pulsed exposure (PE), antibiotics were used 
after phagocytosis. The drugs were applied at their peak concentrations 
in serum in both cases. It was indicated that even a brief exposure of M. 
avium to peak concentrations of some agents in serum may lead to 
prolonged and persistent suppression of bacterial growth in human 
macrophages[31]. 
As an intracellular pathogen, M. tuberculosis suppresses 
macrophage apoptosis to support survival and replication within the host 
cell. Jayakumar et al demonstrated that the functional serine/threonine 
kinase, PknE, is essential for survival of M. tuberculosis which enhances 
macrophage viability by inhibiting apoptosis. A promoter of PknE was 
shown to respond to nitric oxide stress. Deletion of pknE in M. 
tuberculosis resulted in an increased-resistance strain to nitric oxide 
donors and a more-sensitive strain to reducing agents. The deletion 
mutant caused by specialized transduction induced apoptosis while 
inhibiting necrosis[32].  
According to Basler et al murine macrophage cell lines are a 
suitable system to examine M. avium ssp. patho-mechanisms and could 
dispaly that MAP, but not MAA, specifically inhibited the antigen-specific 
stimulatory capacity for CD4(+) T-cells[33].  
Lee et al[1] examined the roles of SigB and SigF in sigma factor 
regulation in M. tuberculosis in terms of their physiological effects of 
transcriptional activation by testing the growth of the sigB and sigF KI 
strains during macrophage infection. It was indicated that baseline sigB 
and sigF expressions in the KI strains were higher than those in the 
control strains because of the increased gene dosage and leakiness of the 
acetamide promoter system. Even with the acetamide-free conditions, M. 
tuberculosis recombinants overexpress sigB and sigF. The sigB KI strain 
demonstrated a growth defect in macrophages, because it could not 
replicate at the same rate as the control strain. Similarly, the normalized 
CFU counts showed a reduced growth rate for the sigB-overexpressing 
strain compared with the control strain. The CFU counts for the sigF-
overexpressing strain also displayed a slowed intracellular growth rate. 
Although macrophages are effective in internalizing and 
clearing most of the bacteria, M. tuberculosis H37Rv has evolved some 
effective survival strategies, which include inhibiting phagosome-
lysosome fusion, inhibiting phagosome acidification, recruiting and 
retaining tryptophan-aspartate with coat protein on phagosomes to 
prevent their delivery to lysosomes and expressing members of the host-
induced repetitive glycine-rich protein family of proteins[34].  
Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the 
first key step of gluconeogenesis. Marrero et al applied genetic analyses 
and (13) C carbon tracing to show that PEPCK is crucial for growth of M. 
tuberculosis on fatty acids and increases the rate of carbon flow from 
tricarboxylic acid cycle-derived metabolites to gluconeogenic 
intermediates. It was further shown that PEPCK is a must for growth of 
M. tuberculosis in a murine macrophage model and in mice. In addition, 
M. tuberculosis without PEPCK failed to replicate in mouse lungs, and 
could not survive, while PEPCK depletion in chronic phase of infection 
caused mycobacterial clearance. M. tuberculosis is therefore based on 
gluconeogenesis during the infection. PEPCK depletion weakens M. 
tuberculosis in IFN gamma-deficient mice, suggesting that this enzyme 
could be a target for chemotherapy[35]. 
Bordbar et al developed a cell-specific alveolar macrophage 
model, iAB-AMØ-1410, and then integrated it with an M. tuberculosis 
H37Rv model, iNJ661, to construct an integrated host-pathogen genome-
scale reconstruction, iAB-AMØ-1410-Mt-661. The integrated model 
allows the simulation of the metabolic changes during infection which 
shows three distinct pathological states[36].  
2.3.3 Immunomechanism of Tuberculosis 
According to Jayakumar et al the pknE mutant alters the innate 
immune response as displayed by the decrease in the pro-inflammatory 
cytokines in a macrophage model[32].  
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In terms of the pathophysiological functions of proline-
glutamic acid (PE)/proline-proline-glutamic acid (PPE) family of proteins 
of M. tuberculosis, Nair et al demonstrated in their study that one of the 
PPE proteins, PPE18, can stimulate macrophages to secrete IL-10 which 
favors a Th2 type response. When macrophages were infected with a 
mutant M. tuberculosis strain lacking the PPE18, less IL-10 was produced 
as compared with those infected with the wild-type strain. The evidence 
suggests that the PPE18 protein may initiate an anti-inflammatory 
response by stimulating IL-10 production[9].  
Pichugin et al used a mouse model of infection with M. 
tuberculosis to figure out the functioning of the genetic locus sst1 in hosts 
developing pulmonary tuberculosis. It is indicated that sst1 can control 
necrosis within tuberculosis lesions in the lung, which is independent of 
both the route of infection and the host’s genetic background. What for 
more, sst1-dependent necrosis took place at low bacterial loads in the 
lung after anti-tuberculosis drug therapy was stopped. As a result, sst1-
susceptible mice with tuberculosis-resistant and -susceptible genetic 
backgrounds can be used to reproduce different types of clinical 
pulmonary tuberculosis and may be applied to predict the efficacy of 
anti-tuberculosis drugs for different human populations[7].  
T cell immunoglobulin and mucin domain 3 (Tim3) is a 
negative regulatory molecule that suppresses effector T(H)1-type 
responses. Such inhibitory signals stop unintended tissue inflammation, 
but can be harmful if they result in premature T cell exhaustion. Despite 
the fact that the role of Tim3 in autoimmunity has been extensively 
explored, whether Tim3 regulates antimicrobial immunity is still 
unknown. According to Jayaraman et al it is demonstrated that Tim3 
expressed on T(H)1 cells interacts with its ligand, galectin-9 (Gal9), 
which is expressed by M. tuberculosis-infected macrophages to inhibit 
intracellular bacterial growth. Tim3-Gal9 interaction activates 
macrophages and increases bactericidal activity by stimulating caspase-
1-dependent IL-1β secretion. The T(H)1 cell surface molecule Tim3 
evolves to restrict the growth of intracellular pathogens via its ligand 
Gal9, which suppresses expansion of effector T(H)1 cells to stop further 
tissue inflammation[37].  
Secretory proteins of M. tuberculosis are the important 
immunomodulators of the host immune response. Open reading frame 
(ORF) Rv2626c, which encodes a conserved hypothetical protein 
inducing a strong humoral immune response in patients with 
tuberculosis (TB), is up-regulated upon infection in mice on hypoxic 
conditions. Bashir et al demonstrate that recombinant Rv2626c protein 
(rRv2626c) can bind to the surface of murine macrophages and lead to 
the type-1 immune response by nitric oxide (NO) secretion and 
expression of inducible nitric oxide synthase (iNOS). Together with 
rRv2626c, significant induction of pro-inflammatory cytokines, which 
include interleukin (IL)-12 and tumour necrosis factor (TNF)-alpha, can 
stimulate murine macrophages and peripheral blood mononuclear cells 
isolated from patients with active TB disease. Stimulation with rRv2626c 
also increases the expression of costimulatory molecules like B7-1, B7-2 
and CD40 on murine macrophages. Furthermore, the production of NO 
and pro-inflammatory cytokines in response to rRv2626c is mediated by 
the transcription factor NF-KB, which is confirmed by using pyrrolidine 
dithiocarbamate, a specific pharmacological inhibitor of NF-KB. Rv2626c 
therefore seems to regulate macrophage effector functions by eliciting 
immune responses[8].  
IL-32 is a cytokine stimulated by M. tuberculosis in a big 
variety of cell types such as human monocytes and macrophages. Bai X et 
al examined the biological significance of IL-32 in an in vitro M. 
tuberculosis infected macrophage model. It is shown that, in THP-1 cells 
infected with M. tuberculosis and stimulated with rIL-32, a higher level of 
apoptosis was seen compared with that with M. tuberculosis infection 
alone. On the other hand, significant abrogation of apoptosis induced by 
M. tuberculosis and a concomitant decrease in caspase-3 activation was 
observed in cells depleted of endogenous IL-32. The rIL-32gamma 
decreased the number of viable M. tuberculosis bacteria, which was 
abolished with a caspase-3 inhibitor. They came to a conclusion that IL-
32 plays a host defense role against M. tuberculosis in a macrophage 
model[14].  
The glutathione-redox balance, which is expressed as the ratio 
of intracellular reduced glutathione and oxidized glutathione, plays an 
essential role to regulate cellular immune responses. Alam et al 
demonstrated in their study that modification of glutathione-redox 
balance in macrophages can differentially regulate the production of IL-
12 cytokine. It is indicated that redox balance of glutathione is an 
important factor that adjusts IL-12 induction in native macrophages, 
while N-acetyl-L-cysteine can tailor macrophages to stimulate enhanced 
Th1 response which may be useful to control tuberculosis and other 
pathophysiological disorders[11].  
Toll-like receptors (TLRs) are important components in the 
regulation of pulmonary immune responses and the recognition of 
respiratory pathogens like M. Tuberculosis. Juarez et al examined human 
alveolar macrophages to define the expression profiles of TLR2, TLR4 
and TLR9. They came to a conclusion that the TLR expression profile of 
autologous human alveolar macrophages and monocytes is not identical, 
which may contribute to compartmentalized immune responses. The 
dissimilarities may have some important implications for the evaluation 
of vaccines with TLR-stimulating adjuvants for the respiratory tract[12].  
 
3. Conclusion 
In regard to cell sources of macrophage models, murine bone 
marrows, human peripheral blood, human lungs, and cell lines are the 
major resources of macrophages for tuberculosis studies.  
The screened antituberculosis drugs include streptomycin, ethambutol, 
pyrazinamide, isoniazid, ceforanide, ciprofloxacin, ofloxacin, rifampin, 
pyrazinamide, rifabutin, clarithromycin, ethambutol, ofloxacin, 
rifapentine, KRM-1648, thiolactomycin, C-8 methoxyl group, C-8-H 
fluoroquinolone, isoxyl, compound 1a of piperazinyl quinolones, 
pittosporum brevicalyx (oliv.) gagnep, cobalt (II) and copper (II) 
complexes of fluorinated isonicotinoylhydrazones, hydrazides, 
isonicotinoylhydrazones, micromolide, 6PP, 8PP, 4,4'-
dihydroxybenzophenone, morphine, ranunculus ternatus thunb, and 
Xinlaoning capsule.  
As to the pathogenesis of tuberculosis, it is indicated from the 
results of studies with macrophage models that, M. tuberculosis H(37)Rv 
has evolved some effective survival strategies, including inhibition of 
phagosome-lysosome fusion and phagosome acidification, recruitment 
and retention of tryptophan-aspartate containing coat protein on 
phagosomes, and expression of the host-induced repetitive glycine-rich 
proteins. The roles of SigB and SigF in sigma factor regulation in M. 
tuberculosis were studied, as a result, it was shown that baseline sigB and 
sigF expressions in the KI strains were higher than those in the control 
strains because of the increased gene dosage and leakiness of the 
acetamide promoter system. Phosphoenolpyruvate carboxykinase 
(PEPCK) is required for growth of M. tuberculosis in isolated bone 
marrow-derived murine macrophages and in mice. M. tuberculosis relies 
on gluconeogenesis throughout the infection. Genes were expressed at a 
much lower level in MAP-infected macrophages than in MAA-infected 
macrophages. Among these were the genes for IL-1beta, IL-1alpha, 
CXCL2, PTGS2 (COX2), lipocalin (LCN2) and TNF, which are essential pro-
inflammatory factors. Infection with MAH also indicated strong induction 
of IL-1beta, CXCL2, COX2, LCN2 and TNF. It is evident that the functional 
serine/threonine kinase is crucial for M. tuberculosis to survive by 
inhibiting apoptosis of macrophages. In addition, it is revealed that a 
short exposure of M. avium to peak concentrations of drugs in serum may 
result in long suppression of bacterial growth in macrophages.  
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The results about immuno-mechanism of tuberculosis from 
studies with macrophage models include: (a)the pknE mutant which 
modifies the innate immune response as shown by the marked decline in 
the pro-inflammatory cytokines in a macrophage model of infection, 
(b)the T(H)1 cell surface molecule Tim3 which inhibits growth of 
intracellular pathogens and expansion of effector T(H)1 cells to stop 
further tissue inflammation, (c) Rv2626c which modulates macrophage 
effector functions by stimulating immune responses, (d) IL-32 playing a 
host defense role against M. tuberculosis, (e) redox balance of glutathione 
playing an essential role in regulating IL-12 induction in macrophages, (f) 
N-acetyl-L-cysteine tailoring macrophages to stimulating enhanced Th1 
response helpful to control tuberculosis, (g) TLR expression of alveolar 
macrophages and monocytes, (h) PPE18 protein triggering an anti-
inflammatory response by inducing IL-10 production, and (i) sst1 
controlling necrosis within tuberculosis lesions in the lungs.  
What could we do for the next step? Here are some questions 
without exact answers. For instance, what is the mechanisms by which M. 
tuberculosis H(37)Rv enters the host cell, circumvents host defenses and 
spreads to neighboring cell? Given the propensity of DHBP for 
nonspecific interactions with proteins, further studies are required to 
figure out a mechanism of DHBP action and to distinguish between the 
bacteriostatic and bactericidal nature of the drug.  
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